Epithalon
Grade CRussian preclinical and small-cohort human studies reported lifespan and biomarker improvements. Independent replication is limited.
Mechanism of Action
Tetrapeptide (Ala-Glu-Asp-Gly) hypothesized to upregulate telomerase activity and normalize pineal melatonin secretion.
Typical Protocol
Dose
5–10 mg
Frequency
Daily
Duration
10–20 day cycles, 2× per year
Timing
Evening
Route
Subcutaneous, intranasal
Half-life
Short, hours
Educational reference only — not medical advice.
Reported Benefits
- Reported telomerase upregulation in cell culture
- Sleep architecture improvement
- Circadian normalization
Side Effects
- Largely unknown long-term
- Injection site reactions
Contraindications
- Active malignancy
- Pregnancy
Known Interactions
MelatoninAdditive effects on pineal signaling.
References
Comparison vs Alternatives
All Peptides →| Attribute | EpithalonThis page | Semaglutide | Retatrutide |
|---|---|---|---|
| Evidence | Grade C | Grade A | Grade A |
| Category | Longevity | Metabolic | Metabolic |
| Best for | Telomerase activation (research) | GLP-1 receptor agonist | Triple GIP/GLP-1/glucagon agonist |
| Typical dose | 5–10 mg | 0.25 → 2.4 mg | Titrated 2 mg → 4 mg → 8 mg → 12 mg |
| Frequency | Daily | Weekly | Once weekly |
| Route | Subcutaneous, intranasal | Subcutaneous weekly (oral form available) | Subcutaneous injection |
| Legal status | Research chemical; not approved for human use. | FDA-approved (Ozempic, Wegovy). Prescription required. | Investigational; not yet FDA-approved. Currently available only via clinical trials. |
| Action | Current page | View → | View → |